Novartis raises FY profit guidance after strong quarter
Investing.com - Novartis (SIX:NOVN) raised its profit guidance Thursday, as the Swiss drugmaker reported second-quarter profit and sales ahead of expectations, boosted by revenue from its blockbuster treatments.
Novartis now expects full-year core operating income to grow by mid- to high teens percentages, from low double-digit to mid-teens, based on strong momentum.
“Novartis delivered a strong Q2, with net sales up 11% and core operating income margin approaching 40%,” said CEO Vas Narasimhan, in a statement. “Our performance reflects continued strong momentum of our key growth drivers, both in the US and ex-US, which has allowed us to upgrade our FY2024 guidance.”
Citi Research has maintained a ‘neutral’ rating, with a CHF97 target price.
“Dynamic growth for most of the key drivers offsetting stronger tail erosion,” said analysts at Citi, in a note. “Despite R&D investments remaining high, FY core EBIT guidance has been raised, and FX impacts moderated, implying consensus earnings upgrades up to 4% and FY24 EBIT/EPS CER [constant exchange rate] growth of 15-19%.”
As far as products are concerned, “Kesimpta was notably strong (9% beat), and Zolgensma beat consensus by 17%,” Citi said. “Cosentyx posted a 4% beat, with the company noting strong launch in HS [hidradenitis suppurativa], partly offset by some one-off adverse pricing impact ex US.”
At 06:20 ET (10:20 GMT), Novartis stock fell 1.4% to CHF97.69 despite the update, but is still up around 15% year to date.
Related Articles
Novartis raises FY profit guidance after strong quarter
Wedbush says Palantir stock could nearly double from here. Here's how
US stock futures mostly rise as chip rout eases; Netflix earnings due